Trial Profile
An Open Label Study to Evaluate the Efficacy and Tolerability of Erenumab in the Management of Persistent Redness and Flushing in Rosacea
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2022
Price :
$35
*
At a glance
- Drugs Erenumab (Primary)
- Indications Rosacea
- Focus Therapeutic Use
- Acronyms STOP ROS Study
- 18 Dec 2021 Status changed from recruiting to completed.
- 09 Jun 2020 Planned End Date changed from 1 Mar 2021 to 1 Aug 2021.
- 09 Jun 2020 Planned primary completion date changed from 30 Jun 2020 to 1 Mar 2021.